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1. Introduction 
Throughout history, various classifications of rhinitis have emerged, many of which 
originated from expert groups. We would have to go back to 1994 to find the “International 
Consensus Report on Diagnosis and Management of Rhinitis” (International Rhinitis 
Management Working Group, 1994), which was subsequently modified in the 2000 
“Consensus statement on the treatment of allergic rhinitis. EAACI Position paper” (Van 
Cauwenberge et al, 2000). Of particular interest is the “Executive Summary of Joint Task Force 
Practice Parameters on Diagnosis and Management of Rhinitis” of 1998 (Dykewicz & Fineman, 
1998). In 2001, a group of experts, the “Allergic Rhinitis and its Impact on Asthma (ARIA) 
Workshop Expert Panel”, met to develop guidelines on the diagnosis and treatment of rhinitis, 
which also dealt with other inflammatory processes interrelated/associated with asthma. 
The acronym “ARIA” comes from “Allergic Rhinitis and its Impact on Asthma”. ARIA is a 
document from a non-governmental organisation of the World Health Organization (WHO), 
endorsed by numerous scientific societies, such as the International Association of 
Allergology and Clinical Immunology (IAACI) and the World Allergy Organization (WAO) 
(Bousquet et al, 2001). 
It was established as an educational program as the “Guidelines for recommendations for 
the diagnosis and comprehensive handling of patients with rhinitis“, associated with 
asthma and other interrelated processes (sinusitis, conjunctivitis and otitis). 
2. The “United airway” concept 
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway hyperresponsiveness 
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that leads to recurrent episodes of wheezing, shortness of breath,   chest tightness, and 
coughing.  These episodes are associated with widespread and variable airflow obstruction 
within the lung, which is often reversible either spontaneously or with treatment (Global 
Initiative for Asthma, Update 2010).  
There is increasing evidence that asthma is a complex syndrome made up of a number of 
disease variants, so-called asthma phenotypes, with different underlying pathophysiologies. 
Limited knowledge of the mechanisms of these disease subgroups is possibly the greatest 
obstacle in understanding the causes of asthma and improving treatment, and can explain 
the failure to identify consistent genetic and environmental correlations to asthma (Lötvall 
et al, 2011). It has been proposed that the asthma syndrome should be divided into distinct 
disease entities with specific mechanisms, which have been called "asthma endotypes." An 
"endotype" is considered to be a subtype of a condition defined by a distinct 
pathophysiological mechanism (Lötvall et al, 2011). 
The ARIA document acknowledged the concept of a “single airway” or “one airway, one 
disease”, in recognition of the indisputable epidemiological and etiopathogenic relationship 
that exists between asthma and allergic rhinitis (AR). Both are “a single disease whose basis 
is the chronic inflammatory process of the airway, a premise that must determine the 
diagnostic and treatment strategy (Bousquet et al, 2008). 
The prevalence of allergic rhinitis in developed countries is between 10%-20%, almost three 
times the prevalence of asthma (Gergen & Turkettaub, 1991; Lester et al, 2001; Mannino et 
al, 2002). The concept “allergy; systemic disease” with clinical manifestations in various 
organs makes “one single airway” more accessible. This way, allergic rhinitis, rhinosinusitis, 
rhinitis with bronchial hyperresponsiveness, asthma, etc., may be reflections of different 
stages of the same chronic inflammatory disease of the airway. 
In our settings, it is important to note that 20.4% of patients visit an allergist for the first time 
for rhinitis and asthma symptoms, as highlighted by the “2005 Allergological Study” 
(Spanish Society of Allergology and Clinical Immunology, 2006). Rhinoconjunctivitis (in 
allergy clinic settings), which was the main reason for visits in the 1992 Allergological Study 
(2,279 patients who represented the 57.4% of the sample) (Spanish Society of Allergology 
and Clinical Immunology, 1995), remains so in the 2005 Allergological Study (2,771 patients 
who represented the 55.5% of the sample) (Spanish Society of Allergology and Clinical 
Immunology, 2006). These absolute rates and figures reflect the importance of this disorder. 
In a study of 650 asthmatics from a health area of the Community of Madrid, 50% had an 
association with allergic rhinitis (Espinosa de los Monteros et al, 1999). 
2.1 Why a new “ARIA document Update 2008” (Bousquet et al, 2008) and “Update 
2010” (Brozek JL et al, 2010)? 
However, during the period between the first edition in 2001 (Bousquet et al, 2001) and the 
present (2012), the appearance of numerous studies have caused it to be revised, giving a 
dynamic and current outlook on the problem both from  epidemiologic and therapeutic 
viewpoints. Thus, the most notable aspect is the inclusion of anti-leukotrienes (Philip G et al, 
2004) and the first mention of Omalizumab (Anti-IgE). Successive meetings of experts, along 
with numerous studies of controlled clinical trials and evidence-based medicine, will 
produce new up-to-date revisions of this document (Bousquet et al, 2008) (Figure 1). 
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Fig. 1. Classification steps for the severity /persistence of allergic rhinitis symptoms with 
various therapy steps. 
The update to the ARIA document is necessary because: 
a. During the period 2001-2012, knowledge of epidemiology, diagnosis, management and 
comorbidity of patients with allergic rhinitis broadened due to the considerable number 
of publications. 
b. The ARIA Recommendations that were proposed by an expert group must be validated 
in terms of classification and management. 
c. New evidence-based medicine systems will guide and include recommendations for 
safety, expenditure and efficacy of various treatments. 
d.  Gaps in the understanding of the first ARIA document: 
 Certain aspects of treatment, such as complementary and alternative medicine. 
 Description of the relationship between upper and lower airways in developing 
countries. 
 The role of rhinitis in athletes. 
 The link between rhinitis and asthma in preschool aged children. 
The rhinitis management (algorithm of the ARIA-Update recommendations 2008 and 2010) 
are shown in Figure 2. 
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Fig. 2. Rhinitis management (algorithm of the ARIA-Update recommendations 2008 and 
2010) (Bousquet et al, 2008; Brozek et al, 2010). 
The initial primary goal of “education and implementation of the handling of allergic 
rhinitis based on the dissemination of information that exists about it, its relationship with 
asthma, as well as allowing scientific evidence (increasingly up-to-date) to be used for 
control, which results in the benefiting of more than 600 million patients who suffer from 
this pathology” has been supplemented by the following news: 
Developments of the 2008- and 2010-ARIA document (Brozek et al, 2010): 
 Confirm the clinical validity of the new allergic rhinitis classification. 
 Better understand the impact of allergic rhinitis on patient quality of life starting with 
the management of rhinitis. 
 Perform a review based on the scientific evidence of all available treatments (published 
trials), including anti-leukotrienes and omalizumab. 
 Emphasize studies that highlight the relationship between rhinitis and asthma. 
 Suggest a plan for implementing the recommendations in Europe (in collaboration with 
the EAACI). 
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 Provide an initial view of the magnitude of the problem with the first strategies in 
developing countries. 
The following Figure 3 presents the degrees of evidence of the various studies in terms of 
each type of treatment (Shekelle et al, 1999; Custovic & Wijk, 2005; Bousquet et al, 2006; 
Passalacqua et al, 2006; Passalacqua & Durham, 2007). 
 
Fig. 3. Level of evidence of different interventions in allergic rhinitis (AR) (Bousquet et al, 2008). 
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The recommendations follow criteria which may differ from country to country, and in Europe 
and at WHO another Shekelle method was commonly used (Shekelle et al, 1999) (Figure 3). 
Strength of recommendation: 
A: Category I evidence (meta-analysis of randomized-controlled trials (RCT); or at least one 
RCT). 
B: Category II evidence (at least one controlled study without randomization; or at least one 
other type of study) or extrapolated recommendation from category I evidence 
C: Category III evidence (nonexperimental descriptive studies) or extrapolated 
recommendation from category I or II evidence. 
D: Category IV evidence (expert committee reports or opinions or clinical experience of 
respected authorities) or extrapolated recommendation from category I, II or III evidence. 
2.3 Controversy in the treatment of allergic rhinitis 
Rhinitis, or inflammation of the nasal mucosa, is currently recognised as a major cause of 
morbidity, which significantly deteriorates quality of life (ISAAC Steering Committee, 1998). 
Although the prevalence of rhinitis is highly variable, we can conclude that between 15% and 
20% of the population suffers from rhinitis, based on various studies that are influenced by the 
questionnaires used and the geographical area in which they are carried out (Broder et al, 
1974a; Broder et al, 1974b; Sibbald & Rink, 1991; Spanish Society of Allergology and Clinical 
Immunology, 1995; Spanish Society of Allergology and Clinical Immunology, 2006). Early 
intervention with appropriate treatment may improve patient quality of life and productivity, 
as well as prevent its evolution to asthma (European Academy of Allergology and Clinical 
Immunology, 1998). A few years ago, the goal of rhinitis treatment was to improve symptoms. 
Currently, the goal is to block pathophysiological mechanisms that cause chronic 
inflammation and that leave patients vulnerable to respiratory airway infections. 
The therapeutic approach to allergic rhinitis (AR) entails comprehensive treatment of the 
allergic inflammation of the airways (ARIA). The selection and combination of the 
therapeutic arsenal is achieved by taking into account current clinical practice guidelines, 
and by individualising the treatment for each patient, depending on the frequency of 
discomfort (intermittent or persistent AR) and its repercussion on the quality of life (mild or 
moderate/severe AR) (Bousquet et al, 2001). Treatment cost-effectiveness must also be 
assessed, as well as safety and the fact that we are dealing with a chronic disease. 
The protocol for managing rhinitis, according to the 1994 Consensus (International Rhinitis 
Management Working Group, 1994), proposes a phased approach for the treatment of both 
allergic and non-allergic rhinitis. The above protocol is not very clear about the indications for 
immunotherapy, which in the final summary is indicated exclusively for seasonal AR. The 
European Academy of Allergy and Clinical Immunology (EAACI) Position Paper for 
treatment of AR published in 2000 and created from consensus between experts of the 
Academy (van Cauwenberge et al, 2000), reviewed 185 articles on rhinitis, focusing exclusively 
on therapeutic issues. The proposed treatment guidelines in this review, differentiated for 
seasonal and perennial AR in children and adults, are too rigid. The indication for 
immunotherapy is envisioned in very advanced phases of the therapeutic range, and also in an 
undefined manner. The therapeutic approach in ARIA (Bousquet et al, 2001) is phased and not 
as rigid as in other consensus. Treatment guidelines are open and do not list directives, and 
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quality of life is assessed through the use of questionnaires. The recommendations for 
treatment depend on symptom severity along with repercussions on patient quality of life. 
For the first time, therapy is approached using evidence-based medical criteria, reviewing 
controlled randomised studies, and performed according to the prior classification of 
seasonal and perennial rhinitis. These recommendations are based on meta-analysis studies 
regarding drug treatment and immunotherapy, and on a clinical practice guideline drawn 
up after an analysis of evidence available to date, based on the opinion of experts regarding 
the elimination of the antigen. 
Of note are considerations regarding drug administration routes, and their 
advantages/disadvantages and indications/contraindications. There is special attention 
given to the intranasal route. 
In 1995, the first manual portable controlled-dose inhaler, called the “Medihaler”, was 
introduced, which was the result of studies carried out in the Richer Co. laboratories (British 
Society for Allergy and Clinical Immunology, 2000). In the USA, a smaller inhaler was 
developed that was easier to handle than nebulizers and avoided the use of sedative 
antihistamines, which alter cognitive and motor functions. The inhaler was developed for 
the asthmatic daughter of Dr. G. Maison, chairman of the laboratories. The inhaler had a 
pressurized canister and metering valve. The use of topical medication in rhinitis has been 
developed to reduce systemic side effects as much as possible. 
2.3 Allergen avoidance 
Although there is disagreement as to the efficacy of eliminating the antigen, it must always 
be carried out using environmental control measures. 
2.4 Therapeutics groups in the “ARIA-pharmaceutical” 
Although there is disagreement as to the efficacy of eliminating the antigen, it must always 
be carried. In recent years, the pharmaceutical industry has researched new administration 
routes. It appears that the nose is a magnificent channel for drugs that until recently could 
only be administered systemically. 
There are eight major therapeutic groups in the “ARIA-pharmaceutical market” available 
use (Table 1). 
 
Drugs Generic names Mechanism of 
action
Side effects Comments 
Local H1-
antihistamines 
(intranasal, 
intraocular) 
Azelastine
Levocabastine
Olopatadine 
Blockage of H1 
receptor. 
Some antiallergic 
activity for 
azelastine.
Minor local side effects.
Azelastine: bitter taste. 
Rapidly effective 
(minor than 30 
minutes) on nasal or 
ocular symptoms. 
Intranasal 
glucocorticoster
oids 
Beclomethason
e dipropionate
Budesonide 
Ciclesonide 
Flunisolide 
Fluticasone 
Potently reduce 
nasal 
inflammation. 
Reduce nasal 
hyperactivity. 
Minor local side effects.
Wide margin for 
systemic side effects. 
Growth concerns with 
BDP only. 
In young children 
The most effective 
pharmacologic 
treatment of allergic 
rhinitis. 
Effective on nasal 
congestion. 
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Drugs Generic names Mechanism of 
action
Side effects Comments 
propionate
Fluticasone 
furoate 
Metasone 
furoate 
Triamcinolone 
acetonide
consider the combination 
of intranasal and inhaled 
drugs. 
Effective on smell. 
Effect observed after 
12 hours but maximal 
effect after a few days 
Leukotriene 
antagonists 
Montelukast
Pranlukast 
Zafirlukast 
Blockage of 
CystLT receptor. 
Excellent tolerance. Effective on rhinitis 
and asthma. 
Effective on all 
symptoms of rhinitis 
and on ocular 
symptoms. 
Local cromones 
(intranasal, 
intraocular) 
Cromoglycate
Nedocromil 
NAAGA 
Mechanism of 
action poorly 
known. 
Minor local side effects. Intraocular cromones 
are very effective.  
Intranasal cromones 
are less effective and 
their effect is short 
lasting.
Intranasal 
anticholinergics 
Ipratropium Anticholinergic 
block almost 
exclusively 
rhinorrhea
Minor local side effects.
Almost no systemic 
anticholinergic activity. 
Effective on allergic 
and non-allergic 
patients with 
rhinorrhea. 
Oral 
decongestants 
Ephedrine
Phenylephrine
Phenylpropan
olamine 
Pseudoephedri
ne 
Oral H1-
antihistamine 
decongestants 
combinations 
Sympathomimetic 
drugs. 
Relieve symptoms 
of nasal 
congestion. 
Hypertension.
Palpitations. 
Restlessness. 
Agitation. 
Tremor. 
Insomnia. 
Headache. 
Dry mucous membranes.
Urinary retention. 
Exacerbation of glau-
coma or thyrotoxicosis.
Use oral decongestants 
with caution in patient 
with heart disease. 
Oral H1-antihistamine-
decongestant 
combination products 
may be more effective 
than either product 
alone but side effects 
are combined. 
Intranasal 
decongestants 
Oxymethazoli
ne 
Xylomethazoli
ne 
Others 
Sympathomimetic 
drugs. 
Relieve symptoms 
of nasal congestion 
Same side affects as oral 
decongestants but less 
intense. 
Rhinitis medicamentosa 
is a rebound phenome-
non occurring with pro-
longed use (over 10 days)
Act more rapidly and 
more effectively than 
oral decongestants. 
Limit duration of 
treatment to minor 10 
days to avoid rhinitis 
medicamentosa. 
Oral/intramusc
ular 
glucocorticoster
oids 
Dexamethason
e 
Hydrocortison
e 
Methylprednis
olone 
Prednisolone 
Prednisone 
Triamcinolone
Potently reduce 
nasal 
inflammation. 
Reduce nasal 
hyperreactivity. 
Systemic side effects 
common in particular for 
intramuscular drugs. 
Depot injections may 
cause local tissue 
atrophy. 
When possible, 
intranasal 
glucocorticosteroids 
should replace oral or 
intramuscular drugs. 
However a short 
course of oral gluco-
corticosteroids may be 
needed of moderate 
/severe symptoms. 
Table 1. Therapeutic groups in the “ARIA-pharmaceutical market” (Bousquet et al, 2008). 
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Topical nasal drugs acts as both a preventive and a curative medication for rhinitis. It is very 
important that the application be performed appropriately, with the goal of achieving 
uniform distribution of the drug throughout the nasal mucosa, especially if rhinorrhoea is 
abundant. 
3. Nasal lavage 
Nasal lavage is a non-pharmacological treatment of rhinitis. Most authors agree that this is a 
well-tolerated, effective and inexpensive treatment. 
3.1 Efficacy in AR 
Georgitis showed that the use of saline solution in nasal irrigation reduces inflammatory 
mediators (nasal histamine, prostaglandin D2 and leukotriene C4), while at the same time 
decreasing nasal symptoms (Georgitis, 1994). It observed that performing nasal lavage is 
important in the treatment of allergic rhinosinusitis. 
Subiza et al, published one of the best and most complete articles in the JACI, which 
indicated that the action of nasal lavages is simple and known: cleaning of nasal secretions, 
with anti-inflammatory effect and reduction in basophils and other anti-inflammatory cells. 
It is a complementary technique for intranasal corticosteroids, but is effective and 
convenient. Saline irrigation of the nose and sinuses during the pollen season inhibits the 
IgE response to grass pollen (Subiza et al, 1999). 
According to Tomooka et al, patients who use nasal lavage twice a day for 3-6 week periods 
have statistically significant improvement (23 of the 30 symptoms on The Quality of Well 
Being scale questionnaires improve or disappear) (Tomooka et al, 2000). 
Garavello et al state that the use of nasal irrigation with hypertonic saline serum (3 times a 
day) decreases the consumption of antihistamines and significantly improves rhinitis, 
starting from the third week of treatment, and clearly in the fourth and fifth, with a 
significant reduction in the use of oral antihistamines (Garavello et al, 2003). The study was 
performed on 20 children, whose ages were not reported, with seasonal AR and 
sensitisation to Parietaria judaica. Irrigation with hypertonic serum was performed on 10 of 
the children 3 times at day during the entire pollen season (6 weeks). The other 10 were not 
administered lavages and were used as controls. 
Degirmencioglu et al showed that saline irrigation with isotonic or hypertonic solutions 
improve symptoms during the pollen season (Degirmencioglu et al, 2004). 
3.2 Usefulness in sinusitis and chronic rhinitis 
Lavages with isotonic and hypertonic saline serum are one of the mainstays of treatment of 
rhinosinusal disease, as they are safe, inexpensive and effective. The weight of evidence is 
such that the Allergy Foundation published an International Consensus article in Allergy 
(International Rhinitis Management Working Group, 1994) recommending the routine 
performance of these lavages for rhinitis. 
Different clinicians confirmed that nasal irrigations with a saline solution along with nasal 
steroids are the basis of treatment for chronic sinusitis (Aukema & Fokkens, 2004). 
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Nevertheless, is cautioned that nasal irrigation with saline solutions could no longer be 
considered a mere adjunct treatment of rhinosinusitis (Brown & Graham, 2004). Despite 
being effective and safe, it is underused. 
Metson lends support to the conviction that saline irrigation improves breathing and adds, 
more importantly, that it lengthens the time between relapses (Metson, 2004). Daily saline 
irrigation improves the quality of life of patients with sinusitis, decreasing symptoms and 
the use of medication (Rabago et al, 2002). 
Nasal irrigation is a simple and inexpensive treatment that improves symptoms of a variety 
of sinonasal diseases, reduces the use of resources and helps minimise resistance to 
antibiotics (Papsin & McTavish, 2003). Also, nasal lavage improves endoscopic imaging of 
nasal mucosa and the quality of life of patients with chronic rhinosinusitis (Taccariello et al, 
1999). The nasal lavage increases mucociliary flow, dilutes thick secretions, relieves irritated 
mucous membranes, eliminates crusts and foreign bodies, facilitates the healing of mucous 
membranes, reducing the need for blowing and improving the sense of smell. The sinus 
irrigation by itself prevented the need for surgery in 58% of patients with chronic sinusitis 
over a year (Hartog et al, 1997) 
4. Antihistamines 
Histamine is one of the main mediators of allergic reactions occurring as a result of contact 
between the allergen and the nasal mucosa. Its actions are not limited to triggering of the 
signs and symptoms of the early phase of the allergic reaction but are also implicated in the 
release of multiple proinflammatory cytokines, with a vasoactive effect that favors arrival in 
the nasal zone of a range of cellular elements that characterize allergic inflammation. 
Antihistamines inhibit the effects of histamine at H1 receptors. Histamine is a 
physiologically active, endogenous substance that binds to and activates histamine H1 and 
H2 receptors in the respiratory tract (including the nose), the gastrointestinal tract, brain, 
adrenal medulla, skin vasculature, and the heart (Golightly & Greos, 2005). 
4.1 Oral antihistamines 
The antihistamines exert a number of effects upon the histamine receptor. On one hand, it is 
now clear that all known antihistamines act as reverse agonists, inactivating the intracellular 
actions of the receptor. On the other hand, antiinflammatory effects have been demonstrated 
for these drugs, explained by modulation of nuclear factor NF-κB, such as the inhibition of 
ICAM-1 expression or action upon the bradykinins (Leurs et al, 2002). 
Antihistamines are classified (Handley et al, 1998) as first generation (sedating, including 
chlorpheniramine, diphenhydramine, promethazine, and hydroxyzine) and newer. The 
newer antihistamines are sometimes referred to as second generation (relatively 
nonsedating, including terfenadine, astemizole, loratadine, cetirizine, and levocetirizine) 
and third generation (including fexofenadine, norastemizole, and descarboethoxyloratadine) 
(Table 2). 
Antihistamine drugs are the most commonly used pharmaceutical group. The effective use 
of anti-H1 (in its oral, intranasal and ophthalmic presentations) for the treatment of AR  
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Chemical class Functional class 
First (old) generation Second (new) generation 
Alkylamines Brompheniramine, 
chlorpheniramine, 
dexchlorpheniramine, 
dimenthindene, pheniramine, 
triprolidine 
Acrivastine 
Piperazines Buclizine, cyclizine, hydroxyzine, 
meclizine, oxatomide 
Cetirizine, levocetirizine 
Piperidines Azatadine, cyproheptadine, 
diphenylpyraline, ketotifen 
Astemizol, bepotastine, 
bilastine, desloratadine, 
ebastine, fexofenadine, 
levocabastine, loratadine, 
mizolastine, rupatadine, 
terfenadine, alcaftadine 
Ethanolamines Carbinoxamine, clemastine, 
dimenhydrinate, 
diphenhydramine, doxylamine, 
phenyltoloxamine 
 
Ethylenediamines Antazoline, pyrilamine, 
tripelennamine 
 
Phenothiazines Methdilazine, promethazine  
Others Doxepin* Azelastine, emedastine, 
epinastine, olopatadine 
* Doxepin has dual H1- and H2- antihistamine activities and is classified as a tricyclic antidepressant. 
Table 2. H1-antihistamines: chemical and functional classification (modified: Simons, 2004; 
Simons & Akdis, 2009; Simons & Simons, 2011). 
(seasonal or perennial) in children or adults is backed by significant evidence from 
published clinical trials (ARIA). 
In the new classification of rhinitis and in the clinical practice guidelines promoted in the 
ARIA document, oral anti-H1 is recommended for use in intermittent and persistent mild 
AR, and combined with topical corticosteroids in persistent moderate/severe AR. It shows 
good response in seasonal AR, where symptoms mediated by histamines predominate and 
ocular symptoms are common. In persistent AR, in which congestion is significant, anti-H1 
has a moderate effect. 
Oral antihistamines may cause subclinical side effects not noticed by the patient 
(somnolence, decreased coordination, etc.). This does not happen with the new non-sedating 
antihistamines, but generally up to 50% of patients self-medicate (Storms, 1997). 
Treatment with antihistamines in AR is almost universally accepted. In fact, the treatment of 
seasonal AR in children: The results of placebo-controlled trials of cetirizine (Allegra et al, 
1993; Masi et al, 1993; Ciprandi et al, 1997a; Ciprandi et al, 1997b; Pearlman et al, 1997) and 
fexofenadine (Wahn et al, 2003) demonstrated significant improvements in symptoms with 
the study drug compared with placebo. Active-control studies compared cetirizine (Charpin 
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et al, 1995) and loratadine (Boner et al, 1989) to first-generation antihistamines, with no 
significant differences between groups. 
Various studies were identified which examined the efficacy of newer antihistamines among 
children with perennial AR (Baelde & Dupont, 1992; Jobst et al, 1994; Charpin et al, 1995; 
Pearlman et al, 1997; Sienra-Monge et al, 1999; Ciprandi et al, 2001; Yang et al, 2001; Lai et al, 
2002; Wahn et al, 2003; Ciprandi et al, 2004; Hsieh et al, 2004). In three studies with active 
controls, cetirizine improved symptoms compared with placebo arms and compared with 
ketotifen and oxatomide (Lai et al, 2002). Cetirizine was comparable to montelukast in one 
study (Hsieh et al, 2004), but similar in efficacy in another (Chen et al, 2006). Three fair-
quality, placebo-controlled studies (Baelde & Dupont, 1992; Jobst et al, 1994; Ciprandi et al, 
2001) found cetirizine efficacious for nasal symptoms, particularly at a dosage of 10 mg daily 
(either at bed time or divided doses twice daily) for children 6 to 12 years. 
4.2 Topical (intranasal) antihistamines 
Up until the late 80s, antihistamines had not yet been developed for local application. In the 
last 20 years, several clinical trials have been carried out on local application of various new 
generation antihistamines. Their marketing and use started almost 15 years ago. 
4.2.1 Azelastine 
Azelastine hydrochloride was initially researched for use in bronchial asthma, and is 
currently used in the symptomatic treatment of seasonal AR and for acute exacerbations of 
perennial AR. It is administered in an aqueous solution as a nasal spray, and was initially 
administered orally. 
Clinical evaluation of its efficacy and side effects were carried out in several multicentre 
studies (Weiler & Meltzer, 1997). It does not affect driving ability or handling of machinery, 
but may occasionally irritate the mucous membrane and cause epistaxis. 
One of the first studies with azelastine was published by Dorow, who performed two 
studies with pollen-allergic patients. The first study compared azelastine with a double-
blind placebo in 16 patients over one week. Significant improvement was noted in the group 
using the drug, with a decrease in sneezing (P<.01) and nasal pruritus (P<.01). There were 
no significant improvements in nasal congestion and hydrorrhoea (Dorow et al, 1993). 
The second study was a double-blind comparison of 36 patients treated with either 
azelastine or budesonide for 15 days. There were no significant differences between the 
groups. 
Weiler studied the effects of pre-treatment with azelastine in nasal provocation with grass 
pollens. Mean percent improvements in the total symptom complex severity scores for 
azelastine were statistically significant (P≤.05) or showed a trend toward statistical 
significance (P<.05 or P≤.10) versus placebo from the second through the first ten hours after 
the initial dose and for each of the last five hours of the second day, demonstrating a rapid 
onset of action and sustained efficacy over the 2-day study period (Weiler & Meltzer, 1997). 
Grossman performed a double-blind study of 199 patients with perennial AR for 8 weeks, 
obtaining significant improvement when compared to placebo (Grossman et al, 1994).  Other 
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studies have compared azelastine nasal spray with other oral antihistamines, finding that its 
efficacy is similar and that it has fewer side effects. 
Conde Hernandez et al compared the safety and efficacy of two antihistamines, azelastine in 
nasal spray and oral ebastine, for 14 days. Authors found no significant differences between 
the two treatments, considering both to be effective in the treatment of seasonal AR (Conde 
Hernández et al, 1995a; Conde Hernández et al, 1995b). 
Berlin et al compared the efficacy of topical nasal corticosteroids with antihistamines in 
nasal spray (azelastine), and found that the results with topical nasal corticosteroids were 
clearly superior for managing nasal symptoms of rhinitis. The authors recommended topical 
nasal corticosteroids as a first-line treatment of perennial AR (Berlin et al 2000). 
4.2.1 Levocabastine 
The first antihistamine developed for nasal application, levocabastine is a highly selective 
histamine antagonist of the H1 receptor, and acts immediately (Janssens et al, 1991). Since it 
is eliminated through the kidneys, it should be used with caution in renal patients. It does 
not sedate or boost the effects of alcohol. The dose is 2 applications of 0.5 mg each every 12 
hours in each nostril. It is more powerful than chlorpheniramine (Dechant & Goa, 1991) and 
similar to other oral antihistamines [loratadine (Swedish GP Allergy Team, 1994) and 
terfenadine (The Livostin Study Group, 1993)] and disodium cromoglycate (Fisher, 1994). 
In 1995, a study was published on 21 patients with AR sensitised to mites. The patients were 
treated with topical levocabastine, and a reduction of inflammatory mediators and nasal 
hyperreactivity was observed. The authors concluded that it was an effective antagonistic of 
H1 receptors, with immediate clinical response and few anti-inflammatory properties (de 
Graaf-in´t Veld et al, 1995). Previously in 1991, other spanish authors showed the efficacy of 
levocabastine in seasonal AR using a double-blind study (Palma-Carlos et al, 1991). 
5. Mast cell membrane stabilising drugs 
Applied topically, these drugs are very useful in mild and moderate AR, as they lack systemic 
effects and are very well tolerated. To achieve effectiveness, appropriate application methods 
must be used so that an even distribution of the medication is achieved, especially if there is 
abundant rhinorrhoea (Okuda et al, 1985). The main drugs being used are: 
5.1 Disodium cromoglycate 
Derived from the natural chromone Khellin, disodium cromoglycate (DSCG) is extracted 
from the Ammi visnaga plant, and was synthesised by Fisons (Cox, 1967). 
It is a dual chromone joined by a flexible chain. The chromone chain has a hydrogen atom 
substituted by a sodium atom. It is a white powder that is barely water-soluble. 
It is administered by inhalation because it is absorbed poorly orally. It has a plasma half-life 
of 80 minutes, and it reaches maximum levels in 20 minutes. 
- Mechanism of action: DSCG has a stabilising effect on the mast cell membrane, 
preventing the release of the chemical mediators responsible for allergic reactions: 
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histamines and eosinophil/neutrophil chemotactic factors. It has no effect on basophils 
(Okuda et al, 1985). It increases the intracellular level of cyclic AMP, inhibiting 
phosphodiesterase and regulating the calcium retention mechanism. 
- Side effects: Side effects are very infrequent. Symptoms may include epistaxis and 
dryness of nasal mucous, sometimes accompanied by sneezing. It is a safe drug, since 
no significant side effects have been reported in long-term treatments. 
The dose is 20-40 mg every 6 hours in each nostril. Therapeutic non-compliance with the 
dosage is the main cause for the lack of spectacular results. 
It is effective in the treatment of AR, especially in patients with high IgE (Okuda et al, 1985). 
It works to prevent sneezing and rhinorrhoea, but not obstruction. 
DSCG performs better than placebo in studies on pollen-sensitized patients. In a double-
blind study that included 104 patients and took place over 6 weeks, authors found 
significant improvement with minimal side effects (Handelman et al, 1977). 
It is important to note that during administration: 
- The container should be protected from light. 
- The aqueous solution should not remain open for more than 30 days. 
- Patient collaboration and discipline is necessary, since application every 6 hours is 
essential. 
- The treatment must not be abandoned due to sneezing during administration, since it is 
usually temporary and lasts only a short time. 
- The drug is mainly preventive and does not, therefore, provide control for patients with 
severe symptoms. 
5.2 Nedocromil sodium 
A pyrano quinoline dicarboxylic acid, nedocromil sodium has a half-life of 90 minutes, and 
is eliminated by the liver and kidneys. It acts extracellularly because it does not pass 
through the lipid membranes due to its physicochemical properties. It acts by blocking the 
chloride channels that are responsible for cellular activity. It inhibits the release of 
histamine, leukotriene C4, prostaglandin D2 and chemotactic factors. 
Although its mechanism of action is similar to DSCG, nedocromil sodium acts on other types 
of cells: eosinophils, neutrophil, macrophages, platelets and monocytes (Kaulbach et al, 1992). 
Side effects are rare, similar to those of DSCG, although nausea, vomiting, dizziness and 
headaches have been reported. It is administered by inhalation in doses of 4 mg twice a day. 
This lower frequency of administration is an advantage over DSCG. Studies demonstrated 
its clinical efficacy in allergic rhinitis. 
5.3 N-acetylaspartylglutamate acid 
The magnesium salts of N-acetylaspartylglutamate (NAAGA) acid are effective in the 
treatment of seasonal allergic rhinitis.  
Althaus performed a multicentre double-blind study for 4 weeks in pollen-allergic patients. 
Sixty-three patients were treated with NAAGA, 63 others with cromolyn sodium and 64 
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with placebo. The efficacy of NAAGA compared to placebo (P<.001) and to cromolyn 
sodium (P<.03) was demonstrated. Terfenadine was used as a rescue medication, requiring 
greater use for placebo than for NAAGA (P<.0001) (Althaus & Pichler, 1994). 
6. Vasoconstrictors (α-adrenergics) 
Vasoconstrictors are sympathomimetic drugs may act on ǂ-receptors, causing 
vasoconstriction, or on ǃ-receptors (vasodilation). The use of ǂ-adrenergics in rhinitis is 
based on its ability to cause vasoconstriction, reducing blood flow in vessels and reducing 
secretions. 
They are widespread in Spain, and should not be administered without medical supervision. 
Those that are used topically are imidazole derivatives: oxymetazoline, naphazoline and 
xylometazoline. They should not be administered for more than 7 days as their prolonged 
use causes the onset of a rebound effect by secondary hyperaemia. This effect occurs a few 
hours after administration and may be interpreted by the patient as a sign of illness, which 
may make them increase the dose. 
Vasoconstrictors have a significant effect on nasal obstruction, but continued use may cause 
drug-induced rhinitis, creating a dependence on nasal drops. Administration to children 
less than 1 year of age is dangerous. 
Based on their study, Graf and Juto recommended avoiding the use of oxymetazoline in 
nasal spray for more than 10 days due to it causing hyperreactivity in the nasal mucosa, thus 
increasing susceptibility to histamines (Graf & Juto, 1994). These authors showed the lack of 
rebound with xylometazoline in nasal spray, when used at the recommended dosage, even 
over twice the recommended time period (Graf & Juto, 1995). 
In the same time, other authors demonstrated the benefit of oxymetazoline above all, and 
xylometazoline somewhat less, in the topical treatment of nasal inflammation of rhinitis, 
due to its antioxidant properties (Westerveld et al, 1995). 
Graf et al, in a study of oxymetazoline, benzalkonium chloride and placebo in nasal spray, 
found that prolonged use (more than recommended) induced an increase in nasal 
hyperreactivity and the feeling of nasal obstruction, developing into secondary drug-
induced rhinitis. This may be related to the presence of benzalkonium in decongestant nasal 
sprays, which can produce or exacerbate drug-induced rhinitis (Graf & Hallen, 1996). Other 
authors performed a 4 to 8-week study with oxymetazoline and showed that it was safe, if 
used once a day, preferably at night (Yoo et al, 1997). 
Moreover, it was confirmed that oxymetazoline and xylometazoline were beneficial in the 
treatment of upper respiratory tract inflammation, due to their dose-dependent inhibitory 
effects on nitric oxide synthase activity (Westerveld et al, 2000) 
Stubner studied the efficacy of cetirizine associated with pseudoephedrine, comparing it to 
xylometazoline at 0.1% in nasal spray. With the exception of nasal obstruction, which 
improved quickly with xylometazoline nasal spray, the rest of the rhinitis symptoms 
(mainly the reduction of nasal secretions) clearly improved with the combination of anti-Hl 
and pseudoephedrine (Stubner et al, 2001). 
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Wellington compared the efficacy of the cetirizine-pseudoephedrine combination (5/120), 
administered twice a day with 100 micrograms of intranasal budesonide for 23 weeks. The 
study found that the cetirizine-pseudoephedrine combination was clearly more effective 
than monotherapy, significantly reducing the score symptoms for both allergic and 
perennial rhinitis, and was also well tolerated (Wellington & Jarvis, 2001). 
7. Conclusions 
Considering the reviewed data, and unifying the above-mentioned opinions on the 
treatment of AR, we provide the following guidelines: 
- Aetiological treatment based on a correct aetiological diagnosis should always be 
achieved. 
- Nasal lavage is a concomitant, non-pharmacological and economical treatment, useful 
in the treatment of AR and especially indicated in chronic rhinosinusitis. 
- New generation antihistamines are the treatment of choice in AR and perhaps the only 
choice for intermittent mild rhinitis. 
- Vasoconstrictors should only be used for a short time when combined with 
antihistamines and/or intranasal corticosteroids when nasal obstruction is not controlled. 
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